Xintela is a biomedical company working in the fields of regenerative medicine and cancer, with particular focus on two areas in which there is great need for new and better treatments: cartilage damage and brain tumours.

Xintela’s operations are based on a patented technology platform, XINMARK™, from which the company makes use of specific markers to develop new treatments and diagnostics in regenerative medicine and cancer. The company is listed on Nasdaq First North Stockholm.